JP2004505965A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505965A5
JP2004505965A5 JP2002518202A JP2002518202A JP2004505965A5 JP 2004505965 A5 JP2004505965 A5 JP 2004505965A5 JP 2002518202 A JP2002518202 A JP 2002518202A JP 2002518202 A JP2002518202 A JP 2002518202A JP 2004505965 A5 JP2004505965 A5 JP 2004505965A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
formula
salt
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002518202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505965A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2001/003561 external-priority patent/WO2002012227A2/en
Publication of JP2004505965A publication Critical patent/JP2004505965A/ja
Publication of JP2004505965A5 publication Critical patent/JP2004505965A5/ja
Pending legal-status Critical Current

Links

JP2002518202A 2000-08-09 2001-08-08 化合物 Pending JP2004505965A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402257 2000-08-09
PCT/GB2001/003561 WO2002012227A2 (en) 2000-08-09 2001-08-08 Indole, azaindole and indazole derivatives having vegf inhibiting activity

Publications (2)

Publication Number Publication Date
JP2004505965A JP2004505965A (ja) 2004-02-26
JP2004505965A5 true JP2004505965A5 (cg-RX-API-DMAC7.html) 2005-03-17

Family

ID=8173808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002518202A Pending JP2004505965A (ja) 2000-08-09 2001-08-08 化合物

Country Status (14)

Country Link
US (2) US20030207878A1 (cg-RX-API-DMAC7.html)
EP (1) EP1311500A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004505965A (cg-RX-API-DMAC7.html)
KR (1) KR20030029812A (cg-RX-API-DMAC7.html)
CN (1) CN1245402C (cg-RX-API-DMAC7.html)
AU (2) AU7993801A (cg-RX-API-DMAC7.html)
BR (1) BR0113078A (cg-RX-API-DMAC7.html)
CA (1) CA2416525A1 (cg-RX-API-DMAC7.html)
IL (1) IL154034A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000874A (cg-RX-API-DMAC7.html)
NO (1) NO20030628L (cg-RX-API-DMAC7.html)
NZ (1) NZ523987A (cg-RX-API-DMAC7.html)
WO (1) WO2002012227A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300489B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144745A0 (en) 1999-02-10 2002-06-30 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
DE60039206D1 (de) 1999-11-05 2008-07-24 Astrazeneca Ab Neue Quinazolin-Derivate
WO2001066099A2 (en) 2000-03-06 2001-09-13 Astrazeneca Ab Use of quinazoline derivatives as angiogenesis inhibitors
BR0109828A (pt) * 2000-04-07 2002-12-17 Astrazeneca Ab Composto, processo para a prepapação do mesmo ou de um sal deste, composição farmacêutica, uso do composto ou de um sal deste farmaceuticamente aceitável, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento
ES2381781T3 (es) 2002-02-01 2012-05-31 Astrazeneca Ab Compuestos de quinazolina
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US6933386B2 (en) * 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003282726B2 (en) * 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
DK1562955T3 (da) 2002-11-04 2008-06-02 Astrazeneca Ab Quinazolinderivater som Src-tyrosinkinaseinhibitorer
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2004218412A1 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
CA2564199A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1751142A1 (en) 2004-05-14 2007-02-14 Pfizer Products Incorporated Pyrimidines derivatives for the treatment of abnormal cell growth
US7851623B2 (en) * 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2012518640A (ja) * 2009-02-23 2012-08-16 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ[4,3−c]シンノリン−3−オンM1受容体陽性アロステリックモジュレーター
US8653079B2 (en) 2011-08-15 2014-02-18 Merck Sharp & Dohme Corp. Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators
NZ728102A (en) * 2014-06-19 2018-04-27 Merial Inc Parasiticidal compositions comprising indole derivatives, methods and uses thereof
US20230041523A1 (en) * 2019-05-14 2023-02-09 Scripps Research Inst Compounds for the treatment of neurodegenerative and metabolic disorders
CN116406271B (zh) * 2020-07-14 2024-09-24 南京再明医药有限公司 双环类化合物
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987332A (en) * 1975-10-09 1976-10-19 Varian Associates Gang tuner for multi-cavity klystron
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5237629A (en) * 1992-03-19 1993-08-17 The United States Of America As Represented By The United States Department Of Energy Digitally controlled distributed phase shifter
US5440270A (en) * 1992-07-14 1995-08-08 Linear Technology Corporation Linear-phase filter having high gain selectivity
SE500986C2 (sv) * 1993-07-20 1994-10-17 Telia Ab Förfarande och anordning för synkronisering i digitalt transmissionssystem av typen OFDM
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP3727406B2 (ja) * 1996-03-07 2005-12-14 株式会社日立国際電気 関数変換演算器
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
KR100446363B1 (ko) * 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
JPH11259454A (ja) * 1998-03-09 1999-09-24 Sharp Corp フーリエ変換装置
BR9912938B1 (pt) * 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
KR200212866Y1 (ko) * 1998-12-26 2001-02-15 서평원 선왜곡 방식 전력증폭기용 능동 왜곡신호 발생회로
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
RU2331640C2 (ru) * 1999-05-21 2008-08-20 Бристол-Маерс Сквибб Ко. Пирролтриазиновые ингибиторы киназ
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
BR0111377A (pt) * 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos

Similar Documents

Publication Publication Date Title
JP2004505965A5 (cg-RX-API-DMAC7.html)
CA2398682A1 (en) Phosphonium and imidazolium salts and methods of their preparation
JP2004533467A5 (cg-RX-API-DMAC7.html)
JP2007523139A5 (cg-RX-API-DMAC7.html)
JP2005525427A5 (cg-RX-API-DMAC7.html)
EP1826196A3 (en) Vinyl ether compounds
JP2004535412A5 (cg-RX-API-DMAC7.html)
CA2549431A1 (en) Optically active quaternary ammonium salt having axial asymmetry and process for producing .alpha.-amino acid and derivative thereof with the same
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
JPH09301934A5 (cg-RX-API-DMAC7.html)
JP2006523241A5 (cg-RX-API-DMAC7.html)
EP1849788A8 (en) Organosilicon compound
EP2088142A3 (en) Dihydropyrimidines, process for their preparation and use thereof.
JP2005519149A5 (cg-RX-API-DMAC7.html)
RU2006121438A (ru) Способ получения бисфосфолановых лигандов
JP2007538042A5 (cg-RX-API-DMAC7.html)
CA2334821A1 (en) Chemical synthesis of morpholine derivatives
JP2005526149A5 (cg-RX-API-DMAC7.html)
EP0357404A3 (en) Process for the preparation of cyclopentane derivatives
JP2006524231A5 (cg-RX-API-DMAC7.html)
JP2005508930A5 (cg-RX-API-DMAC7.html)
WO2003024958A3 (en) Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
JP2005536557A5 (cg-RX-API-DMAC7.html)
JP2012530113A5 (cg-RX-API-DMAC7.html)
JPH09227486A5 (cg-RX-API-DMAC7.html)